Stocktoria
Onconetix, Inc. ONCO
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2022-02-18
Onconetix, Inc. financials (annual)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $815,371 | $2.5M | $58,465 | — | — |
| Gross profit | $632,913 | $1.1M | -$1.1M | — | — |
| R&D expense | — | $154,359 | $1.9M | $4.1M | $1.3M |
| SG&A expense | $7.0M | $11.2M | $14.8M | $9.4M | — |
| Operating income | -$17.9M | -$56.5M | -$36.0M | -$13.5M | -$3.4M |
| Interest expense | — | — | $671,625 | — | — |
| Income tax | $525 | -$1.0M | -$12,593 | $3.16T | $675.7B |
| Net income | -$14.0M | -$58.7M | -$37.4M | -$13.4M | -$3.4M |
| EPS (diluted) | $-16.56 | $-1823.39 | $-87.45 | $-1.10 | $-1.26 |
| Operating cash flow | -$9.7M | -$10.5M | -$13.6M | -$8.7M | -$2.0M |
| Free cash flow | — | -$10.5M | -$13.6M | -$8.7M | -$2.0M |
| Cash & equivalents | — | — | — | $25.8M | $1.9M |
| Inventory | $149,961 | $64,079 | $364,052 | — | — |
| Total assets | $24.9M | $28.2M | $87.5M | $26.3M | $3.1M |
| Total liabilities | $9.2M | $18.6M | $21.9M | $3.9M | $1.6M |
| Shareholders' equity | $15.8M | $8.5M | -$5.6M | $22.4M | $1.4M |
Growth · year-over-year · Revenue CAGR 273.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue growth | -67.7% | +4217.3% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.